• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文OA文献 >Update on Clinical Trials in Dry Age-related Macular Degeneration.
【2h】

Update on Clinical Trials in Dry Age-related Macular Degeneration.

机译：干性年龄相关性黄斑变性临床试验的最新进展。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This review article summarizes the most recent clinical trials for dry age-related macular degeneration (AMD), the most common cause of vision loss in the elderly in developed countries. A literature search through websites https://www.pubmed.org and https://www.clinicaltrials.gov/, both accessed no later than November 04, 2015, was performed. We identified three Phase III clinical trials that were completed over the recent 5 years Age-Related Eye Disease Study 2 (AREDS2), implantable miniature telescope and tandospirone, and several other trials targeting a variety of mechanisms including, oxidative stress, complement inhibition, visual cycle inhibition, retinal and choroidal blood flow, stem cells, gene therapy, and visual rehabilitation. To date, none of the biologically oriented therapies have resulted in improved vision. Vision improvement was reported with an implantable mini telescope. Stem cells therapy holds a potential for vision improvement. The AREDS2 formulas did not add any further reduced risk of progression to advanced AMD, compared to the original AREDS formula. Several recently discovered pathogenetic mechanisms in dry AMD have enabled development of new treatment strategies, and several of these have been tested in recent clinical trials and are currently being tested in ongoing trials. The rapid development and understanding of pathogenesis holds promise for the future.
机译：这篇综述文章总结了干燥年龄相关性黄斑变性（AMD）的最新临床试验，这是发达国家老年人视力丧失的最常见原因。于2015年11月4日之前通过网站https://www.pubmed.org和https://www.clinicaltrials.gov/进行了文献检索。我们确定了最近5年与年龄相关的眼疾研究2（AREDS2），植入式微型望远镜和tandospirone进行的三项III期临床试验，以及针对多种机制的其他几项试验，这些机制包括氧化应激，补体抑制，视觉周期抑制，视网膜和脉络膜血流，干细胞，基因治疗和视觉康复。迄今为止，还没有一种生物定向疗法能够改善视力。据报道，植入式微型望远镜改善了视力。干细胞疗法具有改善视力的潜力。与原始AREDS配方相比，AREDS2配方并未进一步降低进展为晚期AMD的风险。干燥的AMD中最近发现的几种致病机制已促成新治疗策略的开发，其中一些已在最近的临床试验中进行了测试，目前正在进行中。发病机理的迅速发展和理解为未来带来了希望。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号